医薬品ハブ・患者アクセス支援サービスの市場規模、シェア、動向分析レポート：サービスタイプ別、サービス提供タイプ別、地域別、セグメント予測：2024年～2030年

医薬品ハブ・患者アクセス支援サービス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の医薬品ハブ・患者アクセス支援サービスの市場規模は、2024年から2030年にかけてCAGR9.9％を記録し、2030年までには57億米ドルに達すると予測されています。

この成長の背景には、特定の医薬品へのアクセスを必要とする希少疾患や希少疾病患者の著しい増加があります。さらに、患者中心のエコシステムを確立し、治療を通じて患者を手厚くサポートすることが重視され、患者の転帰を改善することを目的としたテーラーメイドのソリューションに対する需要が高まっていることも市場を牽引しています。

希少疾患の蔓延が、医薬品ハブ・患者アクセス支援サービス市場の成長を後押ししています。その背景には、専門的な治療需要、希少疾病治療薬開発へのインセンティブ、希少性による患者アクセス支援の必要性、世界の協力体制、希少疾病治療市場の拡大などがあります。これらの要因により、製薬業界、特に希少疾患の研究開発、患者支援サービスに関連する分野への投資、技術革新、協力が増加しています。

EUでは最大3,600万人が希少疾患の影響を受けており、6,000を超える疾患が存在します。希少疾患の中には、少数の患者しか罹患しないものもありますが、24万5,000人もの患者が罹患するものもあります。これらの疾患の約80％は遺伝的なルーツを持ち、70％は小児期に発症します。さらに米国では、10,000を超える希少疾患が3,000万人以上に影響を及ぼしています。さらに、インドでは人口の6％から8％が希少疾患や超希少疾患に罹患していると推定されています。従って、希少疾患の著しい蔓延が市場成長に寄与すると予想されます。

製薬企業は、患者中心のエコシステムを構築することで、患者のニーズを最優先し、治療を通して患者をサポートするサービスを提供しています。その背景には、適切なトレーニングの不足、服薬不遵守、副作用の恐れ、予約の欠席など、患者の治療に影響を及ぼすさまざまな要因があります。患者は、特定の治療法を処方されるとすぐに、関連する患者サービス・リソースにアクセスし、組織との関わりを開始することができます。

高度なアナリティクスとAI技術により、ペイシェントサービスチームは、治療が進むにつれて、患者一人ひとりのニーズに対応するための実用的な洞察を得ることができます。このようなオーダーメイドのアプローチにより、患者は適切なタイミングで適切なサポートを受けられるようになり、治療成績の向上につながります。例えば、Managed Markets Insight &Technology, LLC、IQVIA、IntegriChainなどの企業は、患者アクセスの障壁を克服するために、このようなソリューションを提供しています。

さらに、ライフサイエンス業界は、統合されたサービスを優先する価値ベースのケアとアウトカム主導モデルに焦点を当てることで、デジタル時代に適応しています。このシフトにより、患者アクセスを向上させ、ヘルスケアのアウトカムを改善する統合ソリューションの技術的進歩が採用されるようになりました。その一例が、TrialCardによる新しいエンタープライズSaaS、ペイシェントリンク・プラットフォームです。2022年4月に発売されたPatientLinkは、患者へのアクセスと患者支援プログラムへの参加を簡素化し、同時に服薬アドヒアランスを向上させます。オムニチャネル体験を提供する高度に設定可能なサービスであり、ライフサイエンス分野のリーダーは、マルチシステムの相互運用性を通じて、要求の厳しいヘルスケアマーケットのニーズに応えることができます。

医薬品ハブ・患者アクセス支援サービス市場レポートハイライト

• サービスタイプ別では、プログラム登録分野が2023年に最大の市場シェアを占めました。その成長の背景には、カスタマイズされたソリューションに対する需要の高まりと、患者の転帰改善に対するニーズの高まりがあります。
• サービス提供タイプ別では、統合サービスセグメントが2023年に最大の市場シェアを占めました。その優位性は、統合ソリューションが患者アクセス支援、償還支援、薬局調整などのさまざまな機能を管理する統一プラットフォームを提供するためです。
• 北米は、2023年に世界市場で最大の収益シェアを占めました。その成長の背景には、糖尿病や心血管障害などの生活習慣病が増加していること、臨床試験に基づく研究が増加していること、この地域における市場プレイヤーの存在感が強いこと、米国などの先進国が存在することなどがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 医薬品ハブ・患者アクセス支援サービス市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連 / 付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 医薬品ハブ・患者アクセス支援サービス市場分析ツール
  • 業界分析 - ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響

第4章 医薬品ハブ・患者アクセス支援サービス市場：サービスタイプの推定・動向分析

• サービスタイプの市場シェア、2023年・2030年
• セグメントダッシュボード
• 世界の医薬品ハブ・患者アクセス支援サービス市場：サービスタイプ別展望
• プログラム登録
• 治療ナビゲーター
• 償還サービス/手頃な価格のサービス
• 臨床教育者
• 専門薬局・調剤のコーディネート
• その他

第5章 医薬品ハブ・患者アクセス支援サービス市場：サービス提供タイプの推定・動向分析

• サービス提供タイプの市場シェア、2023年・2030年
• セグメントダッシュボード
• 世界の医薬品ハブ・患者アクセス支援サービス市場：サービス提供タイプ別展望
• 統合サービス
• スタンドアロンサービス

第6章 医薬品ハブ・患者アクセス支援サービス市場：地域の推定・動向分析、サービスタイプ別、サービス提供タイプ別

• 地域別市場シェア分析、2023年・2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模、予測動向分析、2018年～2030年：
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業 / 競合の分類
  • イノベーター
  • 主要販売代理店・チャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • PharmaCord
  • Fortrea
  • AssistRx
  • CareMetx
  • ConnectiveRx
  • Lash Group
  • McKesson
  • Inizio Engage
  • NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
  • Sonexus Health (acquired by Cardinal Health)
  • Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
  • EVERSANA
  • United BioSource LLC (UBC)
  • Mercalis

List of Tables

• Table 1 List of abbreviation
• Table 2 North America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
• Table 3 North America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 4 North America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 5 U.S. pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 6 U.S. pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 7 Canada pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 8 Canada pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 9 Europe pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
• Table 10 Europe pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 11 Europe pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 12 Germany pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 13 Germany pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 14 UK pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 15 UK pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 16 France pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 17 France pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 18 Italy pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 19 Italy pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 20 Spain pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 21 Spain pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 22 Denmark pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 23 Denmark pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 24 Sweden pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 25 Sweden pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 26 Norway pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 27 Norway pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 31 China pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 32 China pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 33 Japan pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 34 Japan pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 35 India pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 36 South Korea pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 37 South Korea pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 38 Australia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 39 Australia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 40 Thailand pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 41 Thailand pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 42 Latin America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
• Table 43 Latin America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 44 Latin America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 45 Brazil pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 46 Brazil pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 47 Mexico pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 48 Mexico pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 49 Argentina pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 50 Argentina pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 51 MEA pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
• Table 52 MEA pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 53 MEA pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 54 South Africa pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 55 South Africa pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 56 Saudi Arabia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 58 UAE pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 59 UAE pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
• Table 60 Kuwait pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
• Table 61 Kuwait pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Pharma HUB and patient access support service market: market outlook
• Fig. 9 Credentialing software and services competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Pharma HUB and patient access support service market driver impact
• Fig. 15 Pharma HUB and patient access support service market restraint impact
• Fig. 16 Pharma HUB and patient access support service market strategic initiatives analysis
• Fig. 17 Pharma HUB and patient access support service market: Service type movement analysis
• Fig. 18 Pharma HUB and patient access support service market: Service type outlook and key takeaways
• Fig. 19 Program enrollment market estimates and forecast, 2018 - 2030
• Fig. 20 Order processing market estimates and forecast, 2018 - 2030
• Fig. 21 Application processing market estimates and forecast, 2018 - 2030
• Fig. 22 Ease of enrollment (through phone, face, portal, or app) market estimates and forecast, 2018 - 2030
• Fig. 23 Program data market estimates and forecast, 2018 - 2030
• Fig. 24 Treatment navigators market estimates and forecast, 2018 - 2030
• Fig. 25 Process flows and standard operating procedures market estimates and forecast, 2018 - 2030
• Fig. 26 Program literature and scripts market estimates and forecast, 2018 - 2030
• Fig. 27 Care team training market estimates and forecast, 2018 - 2030
• Fig. 28 Systems testing and optimization market estimates and forecast, 2018 - 2030
• Fig. 29 Reimbursement services/affordability services market estimates and forecast, 2018 - 2030
• Fig. 30 Clinical educator market estimates and forecast, 2018 - 2030
• Fig. 31 Coordination of specialty pharmacy/dispensing market estimates and forecast, 2018 - 2030
• Fig. 32 Others market estimates and forecast, 2018 - 2030
• Fig. 33 Pharma HUB and patient access support service market: Service delivery type movement analysis
• Fig. 34 Pharma HUB and patient access support service market: Service delivery type outlook and key takeaways
• Fig. 35 Integrated services market estimates and forecast, 2018 - 2030
• Fig. 36 Standalone services market estimates and forecast, 2018 - 2030
• Fig. 37 Pharma HUB and patient access support service market: Regional movement analysis
• Fig. 38 Pharma HUB and patient access support service market: Regional outlook and key takeaways
• Fig. 39 Pharma HUB and patient access support service market share and leading players
• Fig. 40 North America market share and leading players
• Fig. 41 Europe market share and leading players
• Fig. 42 Asia Pacific market share and leading players
• Fig. 43 Latin America market share and leading players
• Fig. 44 Middle East & Africa market share and leading players
• Fig. 45 North America: SWOT
• Fig. 46 Europe SWOT
• Fig. 47 Asia Pacific SWOT
• Fig. 48 Latin America SWOT
• Fig. 49 MEA SWOT
• Fig. 50 North America, by country
• Fig. 51 North America
• Fig. 52 North America market estimates and forecasts, 2018 - 2030
• Fig. 53 U.S.
• Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 55 Canada
• Fig. 56 Canada market estimates and forecasts, 2018 - 2030
• Fig. 57 Europe
• Fig. 58 Europe market estimates and forecasts, 2018 - 2030
• Fig. 59 UK
• Fig. 60 UK market estimates and forecasts, 2018 - 2030
• Fig. 61 Germany
• Fig. 62 Germany market estimates and forecasts, 2018 - 2030
• Fig. 63 France
• Fig. 64 France market estimates and forecasts, 2018 - 2030
• Fig. 65 Italy
• Fig. 66 Italy market estimates and forecasts, 2018 - 2030
• Fig. 67 Spain
• Fig. 68 Spain market estimates and forecasts, 2018 - 2030
• Fig. 69 Denmark
• Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 71 Sweden
• Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 73 Norway
• Fig. 74 Norway market estimates and forecasts, 2018 - 2030
• Fig. 75 Asia Pacific
• Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 77 China
• Fig. 78 China market estimates and forecasts, 2018 - 2030
• Fig. 79 Japan
• Fig. 80 Japan market estimates and forecasts, 2018 - 2030
• Fig. 81 India
• Fig. 82 India market estimates and forecasts, 2018 - 2030
• Fig. 83 Thailand
• Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 85 South Korea
• Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 87 Australia
• Fig. 88 Australia market estimates and forecasts, 2018 - 2030
• Fig. 89 Latin America
• Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 91 Brazil
• Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 93 Mexico
• Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 95 Argentina
• Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 97 Middle East and Africa
• Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 99 South Africa
• Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 101 Saudi Arabia
• Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 103 UAE
• Fig. 104 UAE market estimates and forecasts, 2018 - 2030
• Fig. 105 Kuwait
• Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 107 Market share of key market players- Pharma HUB and patient access support service market

Pharma HUB And Patient Access Support Service Market Growth & Trends:

The global pharma HUB and patient access support service market size is expected to reach USD 5.7 billion by 2030, registering a CAGR of 9.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the significant prevalence of rare and orphan-diseased patients requiring access to specific medicines. Furthermore, the market is driven by an emphasis on establishing a patient-centered ecosystem to provide extensive support to patients throughout their treatment and an increasing demand for tailored solutions aimed at improving patient outcomes.

The prevalence of rare diseases has fueled growth in the pharmaceutical hub and patient access support service market. It is driven by specialized treatment demand, incentives for orphan drug development, the need for patient access support due to rarity, global collaborative efforts, and an expanding market for rare disease treatments. These factors have led to increased investment, innovation, and collaboration in the pharmaceutical industry, particularly in areas related to rare disease research, development, and patient support services.

Up to 36 million people in the EU are affected by rare diseases, which encompass over 6,000 distinct conditions. While some rare diseases impact only a few patients, others can affect as many as 245,000 individuals. About 80% of these diseases have genetic roots, with 70% beginning in childhood. Furthermore, in the U.S., over 10,000 rare diseases impact more than 30 million people. Moreover, it's estimated that 6-8% of the population in India is affected by rare or ultra-rare diseases. Hence, the significant prevalence of rare diseases is expected to contribute to the market growth.

Pharmaceutical companies are prioritizing the needs of patients by creating a patient-centric ecosystem that offers services to support them throughout their therapy journey. This is due to various factors such as lack of proper training, medication non-adherence, and fear of adverse effects, or missed appointments, which can affect a patient's treatment. Patients can access relevant patient service resources and start engaging with the organization as soon as they are prescribed a particular therapy.

With advanced analytics and AI technology, patient services teams can now obtain actionable insights to cater to each patient's individual needs as they progress through their treatment journey. This tailored approach ensures that patients receive the right support at the right time, leading to better therapy outcomes. For instance, companies such as Managed Markets Insight & Technology, LLC, IQVIA, & IntegriChain are offering such solutions in order to overcome barriers to patient access.

Furthermore, the life sciences industry is adapting to the digital era by focusing on value-based care and outcome-driven models that prioritize integrated services. This shift has led to the adoption of technological advancements in integrated solutions to enhance patient access and improve healthcare outcomes. One such example is the PatientLink platform, a new enterprise SaaS by TrialCard. Launched in April 2022, PatientLink simplifies patient access and engagement with Patient Support Programs while improving adherence to medication. It is a highly configurable service that offers an omnichannel experience, enabling leaders in life sciences to meet the needs of a demanding healthcare marketplace through multi-system interoperability.

Pharma HUB And Patient Access Support Service Market Report Highlights:

• Based on service type, the program enrollment segment held the largest market share in 2023. Its growth can be attributed to growing demand for customized solutions and the increasing need to improve patient outcomes drive
• Based on service delivery type, the integrated services segment held the largest market share in 2023. Its dominance is because the integrated solutions offer a unified platform to manage various functions such as patient access support, reimbursement assistance, and pharmacy coordination
• North America dominated the global market with the largest revenue share in 2023. Its growth can be attributed to the rising prevalence of lifestyle-associated diseases, such as diabetes & cardiovascular disorders, growing number of clinical trial-based research, strong presence of market players in the region, and presence of developed countries, such as the U.S.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Service Type
  • 1.1.2. Service Delivery Type
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service type outlook
  • 2.2.2. Service delivery type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharma HUB And Patient Access Support Service Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharma HUB And Patient Access Support Service Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & legal landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social & environmental landscape
    • 3.3.2.4. Technological landscape
  • 3.3.3. Impact of COVID-19

Chapter 4. Pharma HUB And Patient Access Support Service Market: Service Type Estimates & Trend Analysis

• 4.1. Service Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Pharma HUB And Patient Access Support Service Market by Service Type Outlook
• 4.4. Program Enrollment
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.2. Order processing
    • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.3. Application processing
    • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
    • 4.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4.5. Program data
    • 4.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Treatment Navigators
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Process flows and standard operating procedures
    • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Program literature and scripts
    • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.4. Care team training
    • 4.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.5. Systems testing and optimization
    • 4.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Reimbursement Services/Affordability Services
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Clinical Educator
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.8. Coordination of Specialty Pharmacy/Dispensing
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Pharma HUB And Patient Access Support Service Market: Service Delivery Type Estimates & Trend Analysis

• 5.1. Service Delivery Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Pharma HUB And Patient Access Support Service Market by Service Delivery Type Outlook
• 5.4. Integrated Services
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Standalone Services
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Pharma HUB And Patient Access Support Service Market: Regional Estimates & Trend Analysis, By Service Type, By Service Delivery Type

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Denmark
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Norway
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
  • 7.2.2. List of key distributors and channel partners
  • 7.2.3. Key customers
  • 7.2.4. Key company market share analysis, 2023
  • 7.2.5. PharmaCord
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Fortrea
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. AssistRx
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. CareMetx
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. ConnectiveRx
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Lash Group
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. McKesson
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Inizio Engage
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. Sonexus Health (acquired by Cardinal Health)
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives
  • 7.2.15. Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
    • 7.2.15.1. Company overview
    • 7.2.15.2. Financial performance
    • 7.2.15.3. Product benchmarking
    • 7.2.15.4. Strategic initiatives
  • 7.2.16. EVERSANA
    • 7.2.16.1. Company overview
    • 7.2.16.2. Financial performance
    • 7.2.16.3. Product benchmarking
    • 7.2.16.4. Strategic initiatives
  • 7.2.17. United BioSource LLC (UBC)
    • 7.2.17.1. Company overview
    • 7.2.17.2. Financial performance
    • 7.2.17.3. Product benchmarking
    • 7.2.17.4. Strategic initiatives
  • 7.2.18. Mercalis
    • 7.2.18.1. Company overview
    • 7.2.18.2. Financial performance
    • 7.2.18.3. Product benchmarking
    • 7.2.18.4. Strategic initiatives